CancerDrs

Head and Neck Cancer clinical trials in New Jersey

32 actively recruiting head and neck cancer trials at 25 sites across New Jersey.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Sites in New Jersey:
  • Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
  • Sidney Kimmel Cancer Center Washington Township — Sewell, New Jersey
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Saint Barnabas Medical Center — Livingston, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in New Jersey:
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in New Jersey:
  • Site 94 — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in New Jersey:
  • Jersey City Medical Center — Jersey City, New Jersey
  • Saint Barnabas Medical Center — Livingston, New Jersey
  • Monmouth Medical Center — Long Branch, New Jersey
  • Morristown Medical Center — Morristown, New Jersey
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in New Jersey:
  • Cooper Hospital University Medical Center — Camden, New Jersey
  • Jersey City Medical Center — Jersey City, New Jersey
  • Cooperman Barnabas Medical Center — Livingston, New Jersey
  • Monmouth Medical Center — Long Branch, New Jersey
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in New Jersey:
  • Local Institution - 2122 — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in New Jersey:
  • Englewood Hospital and Medical Center (site 202) — Englewood, New Jersey
  • Summit Medical Group (site 205) — Florham Park, New Jersey
  • Atlantic Health System, Morristown Medical Center (site 124) — Morristown, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07063212
Sites in New Jersey:
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

The purpose of this study is to find out if lower doses of radiation may help reduce the side effects of radiation therapy in combination with standard-of-care chemotherapy in people with HPV-positive throat cancer. The chemotherapy drugs …

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05491512
Sites in New Jersey:
  • Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma

This study will test whether limiting standard photon intensity modulated radiation therapy (IMRT) to exclude the oral tongue surgical site can decrease the risk of side effects caused by oral radiation. The researchers will also find out …

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06485778
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. The resear…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06007924
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free …

Sponsor: Rutgers, The State University of New Jersey
NCT ID: NCT05332002
Sites in New Jersey:
  • RWJBarnabas Health - Robert Wood Johnson University Hospital — Hamilton, New Jersey
  • RWJBarnabas Health - Monmouth Medical Center Southern Campus — Lakewood, New Jersey
  • RWJBarnabas Health - Monmouth Medical Center — Long Branch, New Jersey
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
  • RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

The purpose of this study is to test the treatment approach of de-escalated radiation and chemotherapy followed by a planned neck dissection surgery in people with head and neck cancer. The study will look at how effective the treatment ap…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05544136
Sites in New Jersey:
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of IDP-001 in Advanced or Metastatic Solid Tumors

This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tum…

Sponsor: InduPro, Inc.
NCT ID: NCT07602842
Sites in New Jersey:
  • Hackensack Meridian - John Theurer Cancer Center — Edison, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other canc…

Sponsor: Christian Hinrichs
NCT ID: NCT05686226
Sites in New Jersey:
  • Rutgers Cancer Institute — New Brunswick, New Jersey
  • RWJBarnabas Health - Robert Wood Johnson University Hospital — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)

The purpose of this study is to determine whether treatment of HPV-related oropharyngeal squamous cell carcinoma in patients with undetectable postoperative HPV circulating tumor DNA (cfHPVDNA) with transoral robotic surgery (TORS) alone c…

Sponsor: Icahn School of Medicine at Mount Sinai
NCT ID: NCT05419089
Sites in New Jersey:
  • Valley - Mount Sinai Comprehensive Cancer Care — Paramus, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated cancers. T…

Sponsor: Christian Hinrichs
NCT ID: NCT05639972
Sites in New Jersey:
  • Rutgers Cancer Institute — New Brunswick, New Jersey
  • RWJBarnabas Health - Robert Wood Johnson University Hospital — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in New Jersey:
  • Exelixis Clinical Site #88 — East Brunswick, New Jersey
  • Exelixis Clinical Site #105 — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-d…

Sponsor: IDEAYA Biosciences
NCT ID: NCT07277413
Sites in New Jersey:
  • START Astera, LLC — East Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study …

Sponsor: Pliant Therapeutics, Inc.
NCT ID: NCT06270706
Sites in New Jersey:
  • START New Jersey — East Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether …

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT04722523
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05859074
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
View on ClinicalTrials.gov →

Showing 25 of 32 trials with sites in New Jersey. See all head and neck cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10